Omidian Hossein, Omidian Alborz
Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA.
Department of Psychiatry, Westchester Medical Center, Valhalla, NY 10595, USA.
Pharmaceuticals (Basel). 2025 Mar 29;18(4):499. doi: 10.3390/ph18040499.
Lysergic acid diethylamide (LSD) is gaining renewed interest as a potential treatment for anxiety, depression, and alcohol use disorder, with clinical trials reporting significant symptom reductions and long-lasting effects. LSD modulates serotonin (5-HT2A) receptors, which, in turn, influence dysfunctional brain networks involved in emotional processing and cognition. It has also shown promise in psychedelic-assisted psychotherapy, where mystical-type experiences are linked to improved psychological well-being. This review examines LSD's pharmacokinetics, neurobiological mechanisms, and safety considerations, including cardiovascular risks, emotional vulnerability, and the potential for hallucinogen-persisting perception disorder (HPPD). Challenges such as small sample sizes, variable dosing protocols, and regulatory restrictions limit large-scale trials. Future research should focus on standardization, pharmacogenetic influences, and personalized treatment strategies to ensure its safe and effective integration into clinical practice.
麦角酸二乙酰胺（LSD）作为一种治疗焦虑、抑郁和酒精使用障碍的潜在药物正重新引起人们的关注，临床试验报告称其能显著减轻症状且效果持久。LSD调节血清素（5-HT2A）受体，进而影响参与情绪处理和认知的功能失调的脑网络。它在迷幻辅助心理治疗中也显示出前景，在这种治疗中，神秘体验与改善心理健康相关。这篇综述考察了LSD的药代动力学、神经生物学机制和安全考量，包括心血管风险、情绪易损性以及致幻剂持续性感知障碍（HPPD）的可能性。诸如样本量小、给药方案多变和监管限制等挑战限制了大规模试验。未来的研究应聚焦于标准化、药物遗传学影响和个性化治疗策略，以确保其安全有效地融入临床实践。
